Application of procyanidine in preparation of anti-urinary tract infection and anti-vaginal infection products

By using the combination of proanthocyanin with β-propanolide, vitamin B1 and vitamin B2, effective anti-urinary tract infection and anti-vaginal infection products were prepared, which solved the problem of insufficient antibacterial components in the prior art, and achieved the urinary tract and Effective inhibition of vaginal infection.

CN119055632APending Publication Date: 2024-12-03FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202411326522.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-23
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art lacks effective products against urinary tract and vaginal infection, especially antibacterial ingredients, and long-term use of antibiotics has risks of drug resistance and limitations on use.

Method used

Proanthocyanin is used as the main or only active ingredient, combining β-propanolide, vitamin B1 and vitamin B2 to prepare products that are anti-urinary tract infection and anti-vaginal infection, which reduces bacterial adhesion and cells by inhibiting the physiological activities of bacteria and fungi. Invasion rate.

Benefits of technology

Products made of proanthocyanins significantly reduce the survival rate, adhesion rate and cell invasion rate of bacteria and fungi, have good anti-urinary tract infection and anti-vaginal infection effects, and have good stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055632A_ABST
    Figure CN119055632A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of application of anthocyanin, and particularly relates to application of procyanidine in preparation of products for resisting urinary tract infection and vaginal infection. The infection comprises bacterial infection and fungal infection; the bacteria are escherichia coli, proteusbacillus vulgaris, staphylococcus, pseudomonas aeruginosa and gardnerella vaginalis; the fungi are cryptococcus, aspergillus, mucor, candida and candida albicans. According to the invention, the procyanidine is found to have the effect of resisting urinary tract infection and vaginal infection for the first time, and has good application value in the aspect of preparing anti-infection products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of anthocyanidin application, and specifically relates to the application of proanthocyanidin in the preparation of anti-urinary tract infection and anti-vaginal infection products. Background Art

[0002] Urinary tract infection and vaginal infection are common infectious diseases in women, with high recurrence rates. The current prevention and treatment of these two infections relies on antibiotics such as fluoroquinolones and cephalosporins. However, although antibiotics have a good anti-infection effect for a period of time, their long-term use has the risk of drug resistance and is restricted by pregnancy and lactation. Therefore, it is necessary to develop new products to prevent urinary tract infection and vaginal infection.

[0003] Proanthocyanidins are a class of polyphenolic compounds found in many plants. They are believed to help reduce the risk of heart disease, fight cancer, treat high blood pressure, lower blood lipids and blood sugar, and may also be beneficial to cognitive function and brain health. Due to these health benefits of proanthocyanidins, they are often used as dietary supplements or added to health foods and beverages. Although proanthocyanidins have many uses in the preparation of disease-alleviating products, heart disease, cancer, treatment of high blood pressure, lowering blood lipids and blood sugar are completely different from urinary tract infections and vaginal infections. Whether from the perspective of the cause of the disease, the pathogenic mechanism, or the treatment plan, these diseases are different, and there is no evidence that the treatment drugs for these diseases can be universal. In addition, urinary tract infections and vaginal infections are mainly caused by bacterial or fungal infections. The key to fighting urinary tract infections and vaginal infections is how to better fight bacteria.

[0004] In summary, even if proanthocyanidins have been used to prepare products that relieve many diseases, it cannot be expected that they will be antibacterial, and it is even more impossible to expect proanthocyanidins to be able to resist urinary tract infection and vaginal infection based on the existing technology. According to our search, there is currently no use of proanthocyanidins in the preparation of products that resist urinary tract infection and vaginal infection. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides an application of proanthocyanidins in the preparation of anti-urinary tract infection and anti-vaginal infection products. The present invention finds that proanthocyanidins have the effects of resisting urinary tract infection and vaginal infection, and have good application value in the preparation of anti-infection products.

[0006] The purpose of the present invention is to provide an application of proanthocyanidins in the preparation of products for resisting urinary tract infection and vaginal infection, wherein the infection includes bacterial infection and fungal infection.

[0007] The bacteria are Escherichia coli, Proteus, Staphylococcus, Pseudomonas aeruginosa and Gardnerella vaginalis.

[0008] The fungi are Cryptococcus, Aspergillus, Mucor, Candida and Candida albicans.

[0009] Our experiments have found that proanthocyanidins can inhibit the physiological activity of the above bacteria, and thus have the use of preparing anti-infection products. In addition, the above bacteria and fungi are common causes of urinary tract infection and vaginal infection, and products made from proanthocyanidins have good anti-urinary tract infection and anti-vaginal infection effects.

[0010] Preferably, the product contains proanthocyanidins as the sole active ingredient or the main active ingredient.

[0011] Preferably, when proanthocyanidins are the only active ingredient of the product, the product is a proanthocyanidin solution with a concentration of 32.5 mg / mL to 75 mg / mL. Under this concentration condition, proanthocyanidins have good stability and good anti-infection effect. More preferably, the solvent used to prepare the proanthocyanidin solution is normal saline, wherein the normal saline is a sodium chloride solution with a concentration of 0.9 g / 100 mL.

[0012] Preferably, when proanthocyanidin is used as the main active ingredient, it is compounded with β-propiolactone, vitamin B1 and / or vitamin B2. Wherein, when proanthocyanidin is compounded with β-propiolactone and vitamin B1, the mass ratio of proanthocyanidin, β-propiolactone and vitamin B1 is 40:10:0.3-0.5; when proanthocyanidin is compounded with β-propiolactone and vitamin B2, the mass ratio of proanthocyanidin, β-propiolactone and vitamin B2 is 40:10:0.05-0.07; when proanthocyanidin, β-propiolactone, vitamin B1 and vitamin B2 are compounded, the mass ratio of proanthocyanidin, β-propiolactone, vitamin B1 and vitamin B2 is 40:10:0.3-0.5:0.05-0.07.

[0013] During the research process of the present invention, the information of the active ingredients of anti-infection is as follows:

[0014] The CAS number of proanthocyanidins is 4852-22-6, purchased from Chengdu Lemeitian Pharmaceutical Technology Co., Ltd., the product number is DY0049, and the content of UV is ≥95%.

[0015] β-Propiolactone, also known as β-propioyl lactone, is an organic compound with a chemical formula of C3H4O2. It can inhibit the content of pro-inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-8, thereby achieving an antibacterial effect. β-Propiolactone was purchased from Beijing Bailingwei Technology Co., Ltd. with a purity specification of 98.50%.

[0016] Vitamin B1 is used to nourish nerves. When an infection occurs, the body will have an inflammatory response, causing nerve damage, etc. Vitamin B1 tablets have the effect of repairing nerves and inhibiting the body's production of pro-inflammatory cytokines. Vitamin B1 was purchased from Wuhan Baixing Biotechnology Co., Ltd., with an effective substance content of 98.5%.

[0017] Vitamin B2 is used to enhance the body's immunity and accelerate recovery from illness. Vitamin B2 was purchased from Nanjing Yishengyuan Biotechnology Co., Ltd., with an effective substance content of 99%.

[0018] Both vitamin B1 and vitamin B2 can enhance the anti-infection effects of proanthocyanidins and β-propiolactone.

[0019] Preferably, the above-mentioned proanthocyanidins are used in the preparation of anti-urinary tract infection and anti-vaginal infection products, and the products also include pharmaceutically acceptable excipients. More preferably, the product is a liquid preparation, and the excipients include physiological saline, or the excipients are a miscible substance of glycerol and physiological saline.

[0020] Preferably, in the use of the above-mentioned proanthocyanidins in the preparation of anti-urinary tract infection and anti-vaginal infection products, the auxiliary materials also include at least one of a thickener and a preservative. For example, the thickener is hydroxyethyl cellulose, and the preservative is benzoic acid and its salts, sorbic acid or methyl parahydroxybenzoate.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] Escherichia coli, Proteus, Staphylococcus, Pseudomonas aeruginosa, Gardnerella vaginalis, Cryptococcus, Aspergillus, Mucor, Candida and Candida albicans are common causes of urinary tract infections and vaginal infections. Products made from proanthocyanidins have good anti-urinary tract infection and anti-vaginal infection effects.

[0023] The present invention simulates the vaginal environment and the urethral environment respectively, and explores the antibacterial effect of the product containing proanthocyanidins. The results show that when the bacteria infect HeLa cells, the HeLa cells secrete proinflammatory cytokines TNF-α, IL-1β, IL-6 and IL-8. After being treated with the product containing proanthocyanidins, the content of these proinflammatory factors is reduced and the adhesion rate of the bacteria is reduced; when the bacteria infect the mouse bladder and the human bladder epithelial cell line T24, the adhesion rate of the bacteria is relatively high. After being treated with the product containing proanthocyanidins, the number of colonies, the adhesion rate and the cell invasion rate are significantly reduced. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 This is an exploded view of the use of the present invention. DETAILED DESCRIPTION

[0025] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is further described below in conjunction with specific embodiments and drawings.

[0026] In the description of the present invention, unless otherwise specified, all reagents used are commercially available and all methods used are conventional techniques in the art.

[0027] In the following examples, the physiological saline solution is obtained by sterilizing a 0.9 g / 100 mL sodium chloride solution and cooling it to room temperature.

[0028] Example 1

[0029] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins. The product is a liquid preparation composed of the following ingredients: 80 mg of proanthocyanidins and 2 mL of normal saline.

[0030] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0031] Example 2

[0032] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins. The product is a liquid preparation composed of the following ingredients: 65 mg of proanthocyanidins and 2 mL of normal saline.

[0033] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0034] Example 3

[0035] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins. The product is a liquid preparation composed of the following ingredients: 150 mg of proanthocyanidins and 2 mL of normal saline.

[0036] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0037] Example 4

[0038] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins. The product is a liquid preparation composed of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.3 mg of vitamin B1; and 1 mL of normal saline.

[0039] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins, β-propiolactone and vitamin B1 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0040] Example 5

[0041] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins. The product is a liquid preparation composed of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.4 mg of vitamin B1; and 1 mL of normal saline.

[0042] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins, β-propiolactone and vitamin B1 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0043] Example 6

[0044] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins. The product is a liquid preparation composed of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.5 mg of vitamin B1; and 1 mL of normal saline.

[0045] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins, β-propiolactone and vitamin B1 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0046] Example 7

[0047] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins. The product is a liquid preparation composed of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.05 mg of vitamin B2; and 1 mL of normal saline.

[0048] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolve proanthocyanidins, β-propiolactone and vitamin B2 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilize and cool to room temperature for use.

[0049] Example 8

[0050] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins. The product is a liquid preparation composed of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.06 mg of vitamin B2; and 1 mL of normal saline.

[0051] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolve proanthocyanidins, β-propiolactone and vitamin B2 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilize and cool to room temperature for use.

[0052] Example 9

[0053] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins. The product is a liquid preparation composed of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.07 mg of vitamin B2; and 1 mL of normal saline.

[0054] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolve proanthocyanidins, β-propiolactone and vitamin B2 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilize and cool to room temperature for use.

[0055] Example 10

[0056] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins, the product being a liquid preparation, consisting of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.3 mg of vitamin B1; 0.05 mg of vitamin B2; and 1 mL of normal saline.

[0057] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins, β-propiolactone, vitamin B1 and vitamin B2 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0058] Embodiment 11

[0059] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins, the product being a liquid preparation, consisting of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.4 mg of vitamin B1; 0.06 mg of vitamin B2; and 1 mL of normal saline.

[0060] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins, β-propiolactone, vitamin B1 and vitamin B2 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0061] Example 12

[0062] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins, the product being a liquid preparation, consisting of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.5 mg of vitamin B1; 0.07 mg of vitamin B2; and 1 mL of normal saline.

[0063] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins, β-propiolactone, vitamin B1 and vitamin B2 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0064] Embodiment 13

[0065] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins, the product being a liquid preparation, consisting of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.5 mg of vitamin B1; 0.06 mg of vitamin B2; and 1 mL of normal saline.

[0066] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins, β-propiolactone, vitamin B1 and vitamin B2 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0067] Embodiment 14

[0068] A product for preventing urinary tract infection and vaginal infection prepared from proanthocyanidins, the product being a liquid preparation, consisting of the following ingredients: 40 mg of proanthocyanidins; 10 mg of beta-propiolactone; 0.5 mg of vitamin B1; 0.05 mg of vitamin B2; and 1 mL of normal saline.

[0069] The preparation method of the anti-urinary tract infection and anti-vaginal infection product is as follows: dissolving proanthocyanidins, β-propiolactone, vitamin B1 and vitamin B2 in physiological saline to obtain the anti-urinary tract infection and anti-vaginal infection product, sterilizing and cooling to room temperature for standby use.

[0070] Comparison 1

[0071] A product, which is a liquid preparation, consists of the following ingredients: 10 mg of β-propiolactone and 1 mL of normal saline.

[0072] The beta-propiolactone is dissolved in physiological saline to obtain an anti-urinary tract infection and anti-vaginal infection product, which is sterilized and cooled to room temperature for later use.

[0073] Comparison 2

[0074] A product, which is a liquid preparation, consists of the following ingredients: 0.3 mg vitamin B1; 1 mL normal saline.

[0075] Vitamin B1 is dissolved in physiological saline to obtain an anti-urinary tract infection and anti-vaginal infection product, which is sterilized and cooled to room temperature for later use.

[0076] Comparison 3

[0077] A product, which is a liquid preparation, consists of the following ingredients: 0.05 mg vitamin B2; 1 mL normal saline.

[0078] Vitamin B2 is dissolved in physiological saline to obtain an anti-urinary tract infection and anti-vaginal infection product, which is sterilized and cooled to room temperature for later use.

[0079] Blank control: normal saline.

[0080] In order to demonstrate the anti-infection effect of the present invention, we conducted the following experiments.

[0081] 1. Test materials: Escherichia coli ATCC12435 (hereinafter referred to as Escherichia coli), Proteus vulgaris CMCC(B)49007 (hereinafter referred to as Proteus), Staphylococcus aureus ATCC43300 (hereinafter referred to as Staphylococcus), Gardnerella vaginalis ATCC49145 (hereinafter referred to as Gardnerella vaginalis), Cryptococcus neoformans CBS6956 (hereinafter referred to as Cryptococcus), Aspergillus niger ATCC16404 (hereinafter referred to as Aspergillus), Mucor cladei ATCC28933 (hereinafter referred to as Mucor), Candida albicans ATCC42265 (hereinafter referred to as Candida), Pseudomonas aeruginosa ATCC9027 (hereinafter referred to as Pseudomonas aeruginosa) and Candida albicans ATCC10231 (hereinafter referred to as Candida albicans).

[0082] 2. Experimental product design:

[0083] Example 1 group to Example 14 group correspond to the products prepared in the above-mentioned Example 1 to Example 14, respectively.

[0084] Control group 1 to control group 3 correspond to the products prepared according to the above-mentioned controls 1 to 3, respectively.

[0085] Blank control: normal saline.

[0086] 3. Test methods:

[0087] (1) Antibacterial test

[0088] Different products were added to the culture medium of the above test materials, and the survival rate of the test materials was calculated after 30 minutes. Among them, the concentration of live bacterial strains in the culture medium of bacterial test materials was 10 9 CFU / mL; in the culture medium of fungal test materials, the concentration of live fungi is 10 8 CFU / mL.

[0089] The survival rate was calculated as follows:

[0090]

[0091] (2) Vaginal simulation test

[0092] HeLa cells are human cervical cancer cells that often occur in reproductive organs such as the vagina or uterus. Therefore, we use HeLa cells to conduct in vitro experiments to simulate the anti-infection effects of different products.

[0093] First, a safety test was conducted: HeLa cells were cultured to a cell density of 80% and divided into several test groups. Different products were added to each test group. 100 μL of product was added to every 1 mL of cell fluid. After incubation for 4 hours, the cells were stained with trypan blue and the live cells were counted under an optical microscope. The results were expressed as the percentage of live cells to the total number of cells. There was no significant change in the proportion of live cells, which proved that all products were safe.

[0094] Secondly, a HeLa cell adhesion test was performed: the specific test method was referred to the prior art, such as the adhesion test of patent CN111893057B, wherein the drug treatment was replaced with different products involved in the present invention, and after treatment with different products, the adhesion rates of vaginal Gardnerella and Candida albicans on HeLa cells were counted.

[0095] (3) Urethra test

[0096] First, animal experiments were conducted on female C57BL / 6 mice. 100 μL of different products were injected into the bladder for 2 hours, and then the bacterial solution was injected into the bladder for 2 hours. 5 coli cells; after 4 hours, take out the bladder, wash, homogenize, spread on the plate, incubate at 37℃ overnight, and count the number of colonies.

[0097] Secondly, an in vitro cell experiment was conducted: human bladder cancer epithelial cell line T24, after different products and E. coli were treated with human bladder epithelial cell line T24, the adhesion rate and cell invasion rate of E. coli were calculated. It should be noted that the test method for adhesion rate and cell invasion rate in this section also uses existing technology, and is the same as the adhesion rate test method of the vaginal simulation test, only the test cells have changed.

[0098] 4. Data processing and test results

[0099] Each test group was tested three times in parallel, and the test results were averaged. The safety test results are shown in Tables 1 and 2 below. The results showed that each bacterium and each fungus had at least 99% of live cells. It should be noted that we also conducted safety tests on the human bladder cancer epithelial cell line T24. The test method was based on HeLa cells. The results showed that each product and the corresponding bacteria and fungi also had more than 99% of live cells.

[0100] Table 1 The percentage of living cells of each bacteria (%)

[0101]

[0102] Table 2 The percentage of living cells of each fungus (%)

[0103]

[0104]

[0105] The results of the antibacterial test are shown in Tables 3 and 4. The results show that the survival rates of the products in Example 1 to Example 3, in which anthocyanin is the only active ingredient, are significantly reduced compared to the blank control; the survival rates of the products in each example group in which anthocyanin is compounded with other substances are also significantly reduced compared to the blank control.

[0106] Table 3 Survival rate of each bacteria in the antibacterial test (%)

[0107]

[0108] Table 4 Survival rate of each fungus in the antibacterial test (%)

[0109] Group Cryptococcus Aspergillus Mucor Candida Candida albicans Example 1 Group 25.6±1.5 24.1±2.5 23.4±1.1 25.8±1.8 25.5±0.9 Example 2 Group 24.1±1.2 25.9±2.2 25.0±1.2 24.0±2.6 28.4±0.1 Example 3 Group 30.8±1.3 31.8±0.8 33.5±1.0 34.1±1.4 35.8±0.6 Example 4 Group 20.3±1.6 22.5±1.8 26.1±2.0 25.3±2.3 25.8±1.4 Example 5 Group 20.2±2.0 21.0±1.7 25.6±2.6 26.2±0.3 23.5±2.3 Example 6 Group 19.4±2.2 20.8±2.3 23.4±3.4 25.0±0.1 22.1±2.8 Example 7 Group 19.3±2.1 20.0±2.1 22.2±2.1 23.4±0.5 24.6±2.1 Example 8 Group 18.9±1.5 18.7±0.5 21.2±2.9 24.1±1.2 23.4±0.8 Example 9 Group 19.4±0.9 18.5±2.3 20.4±1.4 24.7±2.1 25.1±0.5 Example 10 Group 6.6±0.8 7.8±1.1 9.4±0.8 9.4±1.1 9.4±0.2 Example 11 Group 5.3±1.3 8.6±0.4 9.1±0.7 9.5±1.0 9.0±0.3 Example 12 Group 6.4±2.4 8.2±0.8 8.5±0.6 9.0±0.9 8.6±1.1 Example 13 Group 5.3±1.7 7.4±1.1 8.9±1.1 8.0±0.8 8.5±0.7 Example 14 Group 6.5±2.0 7.9±0.9 8.8±1.0 8.1±0.9 8.8±1.4 Control group 1 60.8±2.6 62.1±2.3 63.8±5.2 68.5±5.5 65.6±6.7 Control group 2 58.2±4.6 58.9±1.8 61.2±3.7 60.2±3.6 62.4±5.6 Control group 3 57.3±3.1 55.2±2.1 60.7±4.9 60.2±4.4 61.2±0.1 Blank control 100.0±0.0 99.8±0.1 99.1±0.6 99.9±0.1 99.6±0.3

[0110] Using the HeLa cell culture model, sterile deionized water + vaginal Gardnerella + Candida albicans infection triggered the secretion of proinflammatory cytokines TNF-α, IL-1β, IL-6 and IL-8 by HeLa cells; in addition, after treatment with different drugs + vaginal Gardnerella + Candida albicans infection, the test results of cytokine secretion concentration are shown in Table 2. TNF-α, IL-1β, IL-6 and IL-8 were tested using their respective kits. The results of Table 5 show that the products of Examples 1 to 14 of the present invention can inhibit the formation of proinflammatory factors.

[0111] Table 5 Inflammatory factor test results

[0112]

[0113]

[0114] The adhesion rate results of the vaginal simulation test are shown in Table 6. The colony count results, adhesion rate of E. coli, and cell invasion rate results of the urethral test are shown in Table 7. Compared with the control groups, the adhesion rate and other results were significantly reduced.

[0115] Table 6 Adhesion rate of each bacteria in vaginal simulation test (%)

[0116]

[0117]

[0118] Table 7 Urethral simulation test adhesion rate (%)

[0119]

[0120] It should be noted that when the present invention involves a numerical range, it should be understood that the two endpoints of each numerical range and any value between the two endpoints can be selected. Since the steps and methods used are the same as those in the embodiments, in order to avoid redundancy, the present invention describes a preferred embodiment. Although the preferred embodiments of the present invention have been described, once those skilled in the art know the basic creative concept, they can make other changes and modifications to these embodiments, and these changes and modifications all fall within the scope of the present invention.

[0121] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. If these modifications and variations of the present invention fall within the scope of the equivalent technology of the present invention, the present invention is also intended to include these modifications and variations.

Claims

1. Application of proanthocyanidins in the preparation of products against urinary tract infection and vaginal infection, It is characterized in that The infections include bacterial infections and fungal infections; The bacteria are Escherichia coli, Proteus, Staphylococcus, Pseudomonas aeruginosa, and Gardnerella vaginalis; The fungi are Cryptococcus, Aspergillus, Mucor, Candida and Candida albicans.

2. The use of proanthocyanidins according to claim 1 in the preparation of anti-urinary tract infection and anti-vaginal infection products, It is characterized in that The product uses proanthocyanidins as the sole active ingredient or the main active ingredient.

3. Use of the proanthocyanidins according to claim 2 in the preparation of anti-urinary tract infection and anti-vaginal infection products, It is characterized in that When proanthocyanidins are the only active ingredient of the product, the product is a proanthocyanidin solution with a concentration of 32.5 mg / mL to 75 mg / mL.

4. Use of the proanthocyanidins according to claim 3 in the preparation of anti-urinary tract infection and anti-vaginal infection products, It is characterized in that The solvent used to prepare the proanthocyanidin solution is physiological saline.

5. Use of the proanthocyanidins according to claim 2 in the preparation of anti-urinary tract infection and anti-vaginal infection products, It is characterized in that When proanthocyanidins are used as the main active ingredient, the active ingredient of the product is a combination of proanthocyanidins, β-propiolactone and vitamin B1, and the mass ratio of proanthocyanidins, β-propiolactone and vitamin B1 is 40:10:0.3-0.

5.

6. Use of the proanthocyanidins according to claim 2 in the preparation of anti-urinary tract infection and anti-vaginal infection products, It is characterized in that When proanthocyanidins are used as the main active ingredient, the active ingredient of the product is a composition of proanthocyanidins, β-propiolactone and vitamin B2, and the mass ratio of proanthocyanidins, β-propiolactone and vitamin B2 is 40:10:0.05-0.

07.

7. Use of the proanthocyanidins according to claim 2 in the preparation of products against urinary tract infection and vaginal infection, It is characterized in that When proanthocyanidins are used as the main active ingredient, the active ingredient of the product is a combination of proanthocyanidins, β-propiolactone, vitamin B1 and vitamin B2, and the mass ratio of proanthocyanidins, β-propiolactone, vitamin B1 and vitamin B2 is 40:10:0.3-0.5:0.05-0.

07.

8. Use of the proanthocyanidins according to any one of claims 5 to 7 in the preparation of products against urinary tract infection and vaginal infection, It is characterized in that The product also includes pharmaceutically acceptable excipients.

9. Use of the proanthocyanidins according to claim 8 in the preparation of products against urinary tract infection and vaginal infection, It is characterized in that The product is a liquid preparation, and the auxiliary material includes physiological saline, or the auxiliary material is a miscible substance of glycerol and physiological saline.

10. Use of the proanthocyanidins according to claim 9 in the preparation of products against urinary tract infection and vaginal infection, It is characterized in that The auxiliary material also includes at least one of a thickener and a preservative.

Citation Information

Patent Citations

  • A strain of Lactobacillus curvatureis used for the prevention and treatment of urogenital tract infections in women and its application

    CN111893057B

  • Health-care food having assisted function of treating female urinary tract taint

    CN101095764A

  • Application of mixed liquor of anthocyanin extract and corn silk extract to preparation of bacteriostasis medicament

    CN102319369A

  • Bacteriostatic composition for inhibiting vaginal pathogenic bacteria and application of bacteriostatic composition

    CN111084831A

  • Compound vitamin B and application thereof in prevention and treatment of fungal infection

    CN111991400A